Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$29.4 million.

  • Vanda Pharmaceuticals' Cash from Operations fell 151898.73% to -$29.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$109.4 million, marking a year-over-year decrease of 59456.11%. This contributed to the annual value of -$109.4 million for FY2025, which is 59456.11% down from last year.
  • According to the latest figures from Q4 2025, Vanda Pharmaceuticals' Cash from Operations is -$29.4 million, which was down 151898.73% from -$31.6 million recorded in Q3 2025.
  • Vanda Pharmaceuticals' Cash from Operations' 5-year high stood at $31.8 million during Q1 2023, with a 5-year trough of -$33.1 million in Q1 2025.
  • For the 5-year period, Vanda Pharmaceuticals' Cash from Operations averaged around -$810000.0, with its median value being $1.1 million (2022).
  • Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 111356.12% in 2021, then tumbled by 151898.73% in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Cash from Operations stood at $26.6 million in 2021, then tumbled by 64.61% to $9.4 million in 2022, then crashed by 139.63% to -$3.7 million in 2023, then soared by 51.31% to -$1.8 million in 2024, then plummeted by 1518.99% to -$29.4 million in 2025.
  • Its Cash from Operations was -$29.4 million in Q4 2025, compared to -$31.6 million in Q3 2025 and -$15.3 million in Q2 2025.